A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A
- 5 July 2016
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 99, 131-136
Abstract
No abstract availableKeywords
Funding Information
- Tokyo Cooperative Oncology Group
This publication has 26 references indexed in Scilit:
- Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusionMedical Oncology, 2013
- Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space FluidClinical Cancer Research, 2010
- Monoclonal anti‐vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusionRespirology, 2009
- Talc poudrage versus talc slurry in the treatment of malignant pleural effusion.European Journal of Cardio-Thoracic Surgery, 2006
- Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: A randomised trialLung Cancer, 2006
- Vascular endothelial growth factor in pleural effusions of different originEuropean Respiratory Journal, 2005
- Prospective Randomized Trial of Intrapleural Bleomycin Versus Interferon Alfa-2b via Ultrasound-Guided Small-Bore Chest Tube in the Palliative Treatment of Malignant Pleural EffusionsJournal of Clinical Oncology, 2004
- Vascular endothelial growth factor is an autocrine growth factor in human malignant mesotheliomaThe Journal of Pathology, 2001
- Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer CellsThe American Journal of Pathology, 2000
- Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion FormationThe Oncologist, 2000